Cytokinetics Inc. CYTK
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $88.0M | +377% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Operating income | $-612.3M | -14% | FY ending Dec 31, 2025 |
| Net income | $-785.0M | -33% | FY ending Dec 31, 2025 |
| Earnings per share | $-6.54 | -24% | FY ending Dec 31, 2025 |
| Research & development | $416.0M | +23% | FY ending Dec 31, 2025 |
| Cash from operations | $-510.0M | -29% | FY ending Dec 31, 2025 |
| Capital spending | $24.8M | +535% | FY ending Dec 31, 2025 |
| Cash | $122.5M | +29% | FY ending Dec 31, 2025 |
| Long-term debt | $246.4M | +164% | FY ending Dec 31, 2025 |
| Shareholders' equity | $-659.6M | -387% | FY ending Dec 31, 2025 |
| Shares outstanding | 123M | +4% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 78 sales ($51.8M) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $64.01 | $224K | Oct 20, 2026 |
| Robert I BlumPresident & CEO, Director | Sold | 7,500 | $62.88 | $472K | Oct 12, 2026 |
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $61.38 | $215K | Oct 6, 2026 |
| Robert I BlumPresident & CEO, Director | Sold | 7,500 | $65.46 | $491K | Sep 28, 2026 |
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $68.29 | $239K | Sep 22, 2026 |
| Robert I BlumPresident & CEO, Director | Soldpre-set plan | 97,926 | $69.33 | $6.8M | Sep 15, 2026 |
| Robert E LandryDirector | Sold | 1,000 | $72.13 | $72K | Sep 15, 2026 |
| Robert I BlumPresident & CEO, Director | Soldpre-set plan | 7,500 | $73.44 | $551K | Sep 14, 2026 |
| Robert E LandryDirector | Sold | 1,000 | $74.66 | $75K | Sep 11, 2026 |
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $75.46 | $264K | Sep 8, 2026 |
| B Lynne ParshallDirector | Sold | 5,000 | $71.48 | $357K | Sep 1, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sold | 10,000 | $70.24 | $702K | Aug 31, 2026 |
| Robert I BlumPresident & CEO, Director | Sold | 7,500 | $70.24 | $527K | Aug 31, 2026 |
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $75.82 | $265K | Aug 18, 2026 |
| Robert I BlumPresident & CEO, Director | Sold | 7,500 | $76.76 | $576K | Aug 10, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sold | 14,000 | $79.88 | $1.1M | Jul 30, 2026 |
| Robert I BlumPresident & CEO, Director | Sold | 7,500 | $80.87 | $607K | Jul 27, 2026 |
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $80.59 | $282K | Jul 21, 2026 |
| Robert I BlumPresident & CEO, Director | Sold2 fills | 7,500 | $82.02 avg | $615K | Jul 13, 2026 |
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $86.62 | $303K | Jul 7, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sold | 15,000 | $85.80 | $1.3M | Jul 1, 2026 |
| Robert I BlumPresident & CEO, Director | Sold | 7,500 | $84.92 | $637K | Jul 1, 2026 |
| Sung LeeEVP, Chief Financial Officer | Sold | 1,112 | $87.79 | $98K | Jul 1, 2026 |
| Sung LeeEVP, Chief Financial Officer | Sold | 3,134 | $85.00 | $266K | Jun 29, 2026 |
| Sung LeeEVP, Chief Financial Officer | Sold | 38,730 | $82.30 | $3.2M | Jun 24, 2026 |
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $79.51 | $278K | Jun 23, 2026 |
| Robert I BlumPresident & CEO, Director | Sold | 7,500 | $70.46 | $528K | Jun 15, 2026 |
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $67.98 | $238K | Jun 9, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sold | 15,000 | $74.08 | $1.1M | Jun 1, 2026 |
| B Lynne ParshallDirector | Sold | 5,000 | $74.08 | $370K | Jun 1, 2026 |
| Edward M. Md KayeDirector | Sold | 2,933 | $76.09 | $223K | Jun 1, 2026 |
| Robert I BlumPresident & CEO, Director | Sold | 7,500 | $77.21 | $579K | May 27, 2026 |
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $75.69 | $265K | May 19, 2026 |
| Robert I BlumPresident & CEO, Director | Sold | 7,500 | $77.92 | $584K | May 14, 2026 |
| Sung LeeEVP, Chief Financial Officer | Sold | 23,906 | $76.87 | $1.8M | May 5, 2026 |
| John T HendersonDirector | Sold | 20,000 | $75.97 | $1.5M | May 5, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sold | 11,333 | $77.25 | $875K | May 5, 2026 |
| Wendell WierengaDirector | Sold | 4,032 | $75.00 | $302K | May 5, 2026 |
| Fady Ibraham MalikEVP Research & Development | Sold | 3,500 | $77.37 | $271K | May 5, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Sold | 15,857 | $65.00 | $1.0M | May 1, 2026 |
Other insider moves (103): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Oct 20, 2026 |
| John T HendersonDirector | Award | 352 | $63.92 | $22K | Oct 16, 2026 |
| Edward M. Md KayeDirector | Award | 195 | $63.92 | $12K | Oct 16, 2026 |
| Robert Arthur HarringtonDirector | Award | 195 | $63.92 | $12K | Oct 16, 2026 |
| James M DalyDirector | Award | 195 | $63.92 | $12K | Oct 16, 2026 |
| Nancy WysenskiDirector | Award | 97 | $63.92 | $6,200 | Oct 16, 2026 |
| Wendell WierengaDirector | Award | 97 | $63.92 | $6,200 | Oct 16, 2026 |
| Robert I BlumPresident & CEO, Director | Option exercise | 7,500 | $10.60 | $80K | Oct 12, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Oct 6, 2026 |
| Robert I BlumPresident & CEO, Director | Option exercise | 7,500 | $10.60 | $80K | Sep 28, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Sep 22, 2026 |
| Robert I BlumPresident & CEO, Director | Option exercisepre-set plan | 7,500 | $10.60 | $80K | Sep 14, 2026 |
| Robert I BlumPresident & CEO, Director | Giftpre-set plan2 fills | 99,276 | – | – | Sep 14, 2026 |
| Robert I BlumPresident & CEO, Director | Giftpre-set plan | 97,926 | – | – | Sep 14, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Sep 8, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Option exercise | 10,000 | $23.26 | $233K | Aug 31, 2026 |
| Robert I BlumPresident & CEO, Director | Option exercise | 7,500 | $10.60 | $80K | Aug 31, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Aug 18, 2026 |
| Robert I BlumPresident & CEO, Director | Option exercise | 7,500 | $10.60 | $80K | Aug 10, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Option exercise | 14,000 | $23.26 | $326K | Jul 30, 2026 |
| Robert I BlumPresident & CEO, Director | Option exercise | 7,500 | $10.60 | $80K | Jul 27, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Jul 21, 2026 |
| John T HendersonDirector | Award | 272 | $82.62 | $22K | Jul 15, 2026 |
| Edward M. Md KayeDirector | Award | 151 | $82.62 | $12K | Jul 15, 2026 |
| Robert Arthur HarringtonDirector | Award | 151 | $82.62 | $12K | Jul 15, 2026 |
| James M DalyDirector | Award | 151 | $82.62 | $12K | Jul 15, 2026 |
| Nancy WysenskiDirector | Award | 75 | $82.62 | $6,196 | Jul 15, 2026 |
| Wendell WierengaDirector | Award | 75 | $82.62 | $6,196 | Jul 15, 2026 |
| Robert I BlumPresident & CEO, Director | Option exercise | 7,490 | $10.60 | $79K | Jul 13, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Jul 7, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Option exercise | 15,000 | $23.26 | $349K | Jul 1, 2026 |
| Sung LeeEVP, Chief Financial Officer | Option exercise | 1,112 | $48.51 | $54K | Jul 1, 2026 |
| Sung LeeEVP, Chief Financial Officer | Option exercise5 fills | 3,134 | $45.83 avg | $144K | Jun 29, 2026 |
| Sung LeeEVP, Chief Financial Officer | Option exercise7 fills | 38,730 | $47.10 avg | $1.8M | Jun 24, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Jun 23, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Jun 9, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Option exercise | 15,000 | $23.26 | $349K | Jun 1, 2026 |
| Muna BhanjiDirector | Award | 2,851 | – | – | May 27, 2026 |
| James M DalyDirector | Award | 2,851 | – | – | May 27, 2026 |
| Robert Arthur HarringtonDirector | Award | 2,851 | – | – | May 27, 2026 |
| John T HendersonDirector | Award | 2,851 | – | – | May 27, 2026 |
| Edward M. Md KayeDirector | Award | 2,851 | – | – | May 27, 2026 |
| B Lynne ParshallDirector | Award | 2,851 | – | – | May 27, 2026 |
| Robert E LandryDirector | Award | 2,851 | – | – | May 27, 2026 |
| Wendell WierengaDirector | Award | 2,851 | – | – | May 27, 2026 |
| Nancy WysenskiDirector | Award | 2,851 | – | – | May 27, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | May 19, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Option exercise | 11,333 | $39.13 | $443K | May 5, 2026 |
| John T HendersonDirector | Option exercise | 20,000 | $7.61 | $152K | May 5, 2026 |
| Wendell WierengaDirector | Option exercise | 4,032 | $12.40 | $50K | May 5, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | May 5, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Option exercise | 15,857 | $37.63 | $597K | May 1, 2026 |
| Andrew CallosEVP, Chief Commercial Officer | Option exercise | 15,000 | $23.26 | $349K | Apr 30, 2026 |
| Fady Ibraham MalikEVP Research & Development | Option exercise | 3,500 | $7.80 | $27K | Apr 21, 2026 |
| John T HendersonDirector | Award | 325 | $65.37 | $21K | Apr 15, 2026 |
| Edward M. Md KayeDirector | Award | 191 | $65.37 | $12K | Apr 15, 2026 |
| Robert Arthur HarringtonDirector | Award | 191 | $65.37 | $12K | Apr 15, 2026 |
| James M DalyDirector | Award | 191 | $65.37 | $12K | Apr 15, 2026 |
| Nancy WysenskiDirector | Award | 95 | $65.37 | $6,210 | Apr 15, 2026 |
| Wendell WierengaDirector | Award | 95 | $65.37 | $6,210 | Apr 15, 2026 |
Trades by members of Congress
2 members reported 4 buys and 1 sale since Jun 11, 2025. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. D | Bought | $1,001–$15K | Sep 29, 2026 | Oct 12, 2026 | Self |
| Gilbert Ray Cisneros, Jr. D | Bought | $1,001–$15K | Jun 30, 2026 | Jul 2, 2026 | Self |
| Gilbert Ray Cisneros, Jr. D | Bought | $1,001–$15K | Oct 9, 2025 | Nov 18, 2025 | Self |
| Lisa C. McClain R | Sold | $1,001–$15K | Jun 17, 2025 | Aug 13, 202557 days later | Spouse |
| Lisa C. McClain R | Bought | $1,001–$15K | Jun 11, 2025 | Aug 13, 202563 days later | Spouse |
Latest SEC filings
- Insider plans to sell 144 · Oct 20, 2026
- Insider plans to sell 144 · Oct 13, 2026
- Insider plans to sell 144 · Sep 15, 2026
- Insider plans to sell 144 · Sep 11, 2026
- Insider plans to sell 144 · Sep 1, 2026
- News filing: Other news 8-K · Aug 28, 2026
- News filing: Other news 8-K · Aug 13, 2026
- Quarterly report 10-Q · Aug 6, 2026
- News filing: Quarterly results 8-K · Aug 6, 2026
- Insider plans to sell 144 · Jul 30, 2026
- Insider plans to sell 144 · Jul 7, 2026
- Insider plans to sell 144 · Jul 1, 2026
- Insider plans to sell 144 · Jun 29, 2026
- Insider plans to sell 144 · Jun 26, 2026
- Insider plans to sell 144 · Jun 24, 2026
- Insider plans to sell 144 · Jun 1, 2026
- News filing: Shareholder vote results 8-K · May 27, 2026
- News filing: Other news 8-K · May 8, 2026
- Insider plans to sell 144 · May 5, 2026
- Insider plans to sell 144 · May 5, 2026
- Insider plans to sell 144 · May 5, 2026
- News filing: Other news 8-K · May 5, 2026
- Quarterly report 10-Q · May 5, 2026
- News filing: Quarterly results 8-K · May 5, 2026
- Shareholder meeting proxy DEF 14A · Apr 17, 2026
About Cytokinetics Inc.
Business description
- Industry
- Pharmaceutical Preparations
- Sector
- Life Sciences
- Headquarters
- South San Francisco, CA
- Fiscal year ends
- December 31
- Exchange
- Nasdaq
- Filer size
- Large accelerated filer
- SEC company number (CIK)
- 1061983
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.